Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis

Inflammatory Bowel Diseases

Volumn 10, Issue 3, 2004, Pages 182-192

  Mizushima, Tsunekazu ^a   Ito, Toshinori ^a   Kishi, Daisuke ^a   Kai, Yasuyuki ^b   Tamagawa, Hiroshi ^a   Nezu, Riichiro ^b   Kiyono, Hiroshi ^c   Matsuda, Hikaru ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

FTY720; Inflammatory bowel disease; Interleukin 10 gene deficient mice; Lymphocyte homing

Indexed keywords

CYTOKINE; FINGOLIMOD; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC DISEASE; CLINICAL FEATURE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HISTOPATHOLOGY; IMMUNE DEFICIENCY; LAMINA PROPRIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE HOMING; LYMPHOID TISSUE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLITIS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; LYMPHOCYTES; MICE; MICE, INBRED C57BL; PROPYLENE GLYCOLS; SPHINGOSINE; TISSUE DISTRIBUTION;

EID: 2442422272     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200405000-00002     Document Type: Article

References (54)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
2. Strober W, Neurath MF. Immunological disease of the gastrointestinal tract. In: Rich RR, ed. Clinical Immunology. St. Louis, MO: Mosby; 1995:1401-1428.
3. Shanahan F. Crohn's disease. Lancet. 2002;359:62-69.
4. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology. 2000;118:S68-S82.
5. Scribano ML, Prantera C. Medical treatment of active Crohn's disease. Aliment Pharmacol Ther. 2002;16:S35-S39.
6. Rizzello F, Gionchetti P, Venturi A, et al. The management of refractory Crohn's disease. Aliment Pharmacol Ther. 2002;16:S40-S47.
7. Forbes A. Crohn's disease - the role of nutritional therapy. Aliment Pharmacol Ther. 2002;16:S48-S52.
8. Nakase H, Okazaki K, Tabata Y, et al. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther. 2000;292:15-21.
9. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
10. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997;150:823-832.
11. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001;120:622-635.
12. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97:2962-2972.
13. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133.
14. Ito H. Anti-interleukin-6 therapy for Crohn's disease. Curr Pharm Des. 2003;9:295-305.
15. Ding C, Jones G. Technology evaluation: MRA, Chugai. Curr Opin Mol Ther. 2003;5:64-69.
16. Kosaka T, Sawada K, Ohnishi K, et al. Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Intern Med. 1999;38:102-111.
17. Matsui T, Nishimura T, Matake H, et al. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol. 2003; 98:511-512.
18. Adachi K, Kohara T, Arita M, et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1, 3-propanodiols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett. 1995;5:853-856.
19. Fujita T, Yoneta M, Hirose R, et al. Simple compounds, 2-substituted-2-amino-1, 3-propanodiols have potent immunosuppressive activity. Bioorg Med Chem Lett. 1995;5:847-852.
20. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation. 1996;6:200-205.
21. Chen S, Bacon KB, Garcia G, et al. FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. Transplant Proc. 2001;33:3057-3063.
22. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
23. Sartor RB. Role of the intestinal microflora in pathogenesis and complications. In: Scholmerich JH, Goebell W, Kruis W, Hohenberger W, eds. Inflammatory Bowel Diseases: Pathophysiology as Basis of Treatment. London, England: Kluwer Academic, 1992;175-187.
24. Fujihashi K, McGhee JR, Kweon MN, et al. Gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med. 1996;183:1929-1935.
25. Takahashi I, Kiyono H, Hamada S. CD4+ T-cell population mediates development of inflammatory bowel disease in T-cell receptor alpha chain-deficient mice. Gastroenterology. 1997;112:1876-1886.
26. Iijima H, Takahashi I, Kishi D, et al. Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. J Exp Med. 1999;190:607-615.
27. Corazza N, Eichenberger S, Eugster HP, et al. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J Exp Med. 1999;190:1479-1492.
28. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
29. Davidson NJ, Leach MW, Fort MM, et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med. 1996;184:241-251.
30. Davidson NJ, Hudak SA, Lesley RE, et al. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol. 1998;161:3143-3149.
31. Berg DJ, Davidson N, Kuhn P, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98:1010-1020.
32. -/- mice: an overview. J Leukoc Biol. 1997;61:389-396.
33. Lindsay JO, Ciesielski CJ, Scheinin T, et al. The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. J Immunol. 2001;166:7625-7633.
34. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60-66.
35. Kiyono H, Kweon MN, Hiroi T, et al. The mucosal immune system: from specialized immune defense to inflammation and allergy. Acta Odontol Scand. 2001;59:145-153.
36. Iijima H, Takahashi I, Kiyono H. Mucosal immune network in the gut for the control of infectious diseases. Rev Med Virol. 2001;11:117-133.
37. Fiocchi C. The immune system in inflammatory bowel disease. Acta Gastroenterol Belg. 1997;60:156-162.
38. De Keyser F, Elewaut D, De Wever N, et al. The gut associated addressins: lymphocyte homing in the gut. Baillieres Clin Rheumatol. 1996; 10:25-39.
39. Ansel KM, Cyster JG. Chemokines in lymphopoiesis and lymphoid organ development. Curr Opin Immunol. 2001;13(2):172-179.
40. Picarella D, Hurlbut P, Rottman J, et al. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAd-CAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. Immunology. 1997;158:2099-2106.
41. Ludviksson BR, Strober W, Nishikomori R, et al. Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/- mice. J Immunol. 1999;62:4975-4982.
42. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
43. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 1998;160:5037-5044.
44. Yanagawa Y, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing. Immunology. 1998;95:591-594.
45. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol. 2000;164:5761-5770.
46. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J. 2000;349(Pt 2):385-402.
47. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002; 277:21453-21457.
48. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296: 346-349.
49. Watanabe N, Ikuta K, Okazaki K, et al. Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig Dis Sci. 2003;48:408-414.
50. Suzuki S, Li XK, Enosawa S, et al. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology. 1996;89:518-523.
51. Fujino M, Li XK, Guo L, et al. Activation of caspases and mitochondria in FTY720-mediated apoptosis in human T cell line Jurkat. Int Immunopharmacol. 2001;1:2011-2021.
52. Enosawa S, Suzuki S, Kakefuda T, et al. Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720. Immunopharmacology. 1996;34:171-179.
53. Li XK, Tamura A, Fujino M, et al. Induction of lymphocyte apoptosis in rat liver allograft with ongoing rejection by FTY720. Clin Exp Immunol. 2001;123:331-339.
54. MacDonald TT. Effector and regulatory lymphoid cells and cytokines in mucosal sites. Curr Top Microbiol Immunol. 1999;236:113-135.